๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 8 Wuhan 3 Shanghai 2 Hohhot 1 Guandong 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing8 Wuhan3 Shanghai2 Hohhot1 Guandong1
All 12 locations
Target enrolment
to

Trials with a site in Beijing

8 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
NCT07806045IgG4 Related Disease, Systemic Sclerosis (SSc)
Qiubai Li
Phase EARLY_PHASE1
18
Beijing
2026-10-14
Recruiting
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
NCT07148791IgG4 Related Disease, B-cell Mediated Autoimmune Disorders
Chinese PLA General Hospital
Phase 2
9
Beijing
2025-09-05
Recruiting
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
NCT07068165IgG4 Related Disease
Peking Union Medical College Hospital
Phase 2/3
198
Beijing
2025-07-07
Recruiting
Short-term Glucocorticoid Combined with MMF for IgG4-RD
NCT06663618IgG4-related Disease
Wen Zhang
Not applicable
63
Beijing
2023-09-01
Active, closed
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241IgG4 Related Disease
Zenas BioPharma (USA), LLC
Phase 3
194
Beijing, Shijiazhuang, Wuhai, Yantai, Shanghai, Taiyuan, Chengdu
2023-01-09
Active, closed
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497IgG4 Related Disease
Amgen
Phase 3
135
Hohhot, Beijing, Guandong, Shangโ€™ai, Shenyang, Wuhan
2020-12-04
Recruiting
National Registry of IgG4-RD in China
NCT03023371IgG4-Related Disease
Peking Union Medical College Hospital
Observational
900
Beijing
2016-12
Recruiting
A Prospective Cohort Study of IgG4RD in China
NCT01670695IgG4-related Disease
Peking Union Medical College Hospital
Observational
1,000
Beijing
2012-01
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

5 of the 8 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 8 studies
PhaseStudiesRecruitingShare
Observational2225%
Phase 32025%
Not applicable1112.5%
Phase 21112.5%
Phase 2/31112.5%
Phase EARLY_PHASE11012.5%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Peking Union Medical College Hospital33
Amgen10
Chinese PLA General Hospital11
Qiubai Li10
Wen Zhang11
Zenas BioPharma (USA), LLC10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.